Skip to main content

Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory Depression.

Publication ,  Journal Article
Algera, H; van der Schrier, R; Cavalla, D; van Velzen, M; Roozekrans, M; McMorn, A; Snape, M; Horrigan, JP; Evans, S; Kiernan, B; Sarton, E ...
Published in: Anesthesiology
October 1, 2022

BACKGROUND: Animal data suggest that the antidepressant and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor modulator tianeptine is able to prevent opioid-induced respiratory depression. The hypothesis was that oral or intravenous tianeptine can effectively prevent or counteract opioid-induced respiratory depression in humans. METHODS: Healthy male and female volunteers participated in two studies that had a randomized, double blind, placebo-controlled, crossover design. First, oral tianeptine (37.5-, 50-, and 100-mg doses with 8 subjects) pretreatment followed by induction of alfentanil-induced respiratory depression (alfentanil target concentration, 100 ng/ml) was tested. Primary endpoint was ventilation at an extrapolated end-tidal carbon dioxide concentration of 55 mmHg (V̇E55). Next, the ability of four subsequent and increasing infusions of intravenous tianeptine (target tianeptine plasma concentrations 400, 1,000, 1,500, and 2,000 ng/ml, each given over 15 min) to counteract remifentanil-induced respiratory depression was determined in 15 volunteers. Ventilation was measured at isohypercpania (baseline ventilation 20 ± 2 l/min). The primary endpoint was minute ventilation during the 60 min of tianeptine versus placebo infusion. RESULTS: Alfentanil reduced V̇E55 to 13.7 (95% CI, 8.6 to 18.8) l/min after placebo pretreatment and to 17.9 (10.2 to 25.7) l/min after 50-mg tianeptine pretreatment (mean difference between treatments 4.2 (-11.5 to 3.0) l/min, P = 0.070). Intravenous tianeptine in the measured concentration range of 500 to 2,000 ng/ml did not stimulate ventilation but instead worsened remifentanil-induced respiratory depression: tianeptine, 9.6 ± 0.8 l/min versus placebo 15.0 ± 0.9 l/min; mean difference, 5.3 l/min; 95% CI, 2.5 to 8.2 l/min; P = 0.001, after 1 h of treatment. CONCLUSIONS: Neither oral nor intravenous tianeptine were respiratory stimulants. Intravenous tianeptine over the concentration range of 500 to 2000 ng/ml worsened respiratory depression induced by remifentanil.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Anesthesiology

DOI

EISSN

1528-1175

Publication Date

October 1, 2022

Volume

137

Issue

4

Start / End Page

446 / 458

Location

United States

Related Subject Headings

  • alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
  • Thiazepines
  • Respiratory System Agents
  • Respiratory Insufficiency
  • Remifentanil
  • Male
  • Humans
  • Female
  • Double-Blind Method
  • Carbon Dioxide
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Algera, H., van der Schrier, R., Cavalla, D., van Velzen, M., Roozekrans, M., McMorn, A., … Dahan, A. (2022). Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory Depression. Anesthesiology, 137(4), 446–458. https://doi.org/10.1097/ALN.0000000000004324
Algera, Hyke, Rutger van der Schrier, David Cavalla, Monique van Velzen, Margot Roozekrans, Alison McMorn, Michael Snape, et al. “Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory Depression.Anesthesiology 137, no. 4 (October 1, 2022): 446–58. https://doi.org/10.1097/ALN.0000000000004324.
Algera H, van der Schrier R, Cavalla D, van Velzen M, Roozekrans M, McMorn A, et al. Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory Depression. Anesthesiology. 2022 Oct 1;137(4):446–58.
Algera, Hyke, et al. “Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory Depression.Anesthesiology, vol. 137, no. 4, Oct. 2022, pp. 446–58. Pubmed, doi:10.1097/ALN.0000000000004324.
Algera H, van der Schrier R, Cavalla D, van Velzen M, Roozekrans M, McMorn A, Snape M, Horrigan JP, Evans S, Kiernan B, Sarton E, Olofsen E, Niesters M, Dahan A. Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory Depression. Anesthesiology. 2022 Oct 1;137(4):446–458.

Published In

Anesthesiology

DOI

EISSN

1528-1175

Publication Date

October 1, 2022

Volume

137

Issue

4

Start / End Page

446 / 458

Location

United States

Related Subject Headings

  • alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
  • Thiazepines
  • Respiratory System Agents
  • Respiratory Insufficiency
  • Remifentanil
  • Male
  • Humans
  • Female
  • Double-Blind Method
  • Carbon Dioxide